Updated:26 Jul 2017 03:31:00 PM(IST)
|Bse Corporate Announcements||Back|
|Sun Pharmaceutical Industries plans to acquire branded oncology product - Odomzo|
|Sun Pharmaceutical Industries announced its plans to acquire a branded oncology product, Odomzo, from Novartis. The agreement has been signed between subsidiaries of both the companies and will close following anti-trust clearance and further closing conditions. The agreement has been signed for an upfront payment of US$ 175 million and additional milestone payments.
Odomzo® (Sonidegib) was approved by the US FDA in July 2015. Odomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.